C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms.
Samah Alimam,Samah Alimam,Jessica Ann Timms,Jessica Ann Timms,Claire N. Harrison,Claire N. Harrison,Richard Dillon,Richard Dillon,Tracey Mare,Hugues DeLavallade,Hugues DeLavallade,Deepti Radia,Claire Woodley,Yvonne Francis,Katy Sanchez,Shahram Kordasti,Shahram Kordasti,Donal P. McLornan,Donal P. McLornan +18 more
TL;DR: Although, the immune systems of MPN patients can 'recognise' the Influenza A vaccine, the response appears inferior compared to healthy controls.
Journal ArticleDOI
Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.
Yan Beauverd,Yan Beauverd,Samah Alimam,Donal P. McLornan,Donal P. McLornan,Deepti Radia,Claire N. Harrison +6 more
TL;DR: It is suggested that MF in younger patients may have a more indolent course when compared to older patients.
Journal ArticleDOI
JAK Inhibition Reduces CD25 high CD27+ FOXp3+ T Regulatory Cells and Causes a Silencing Of T Effector Cells In Patients With Myeloproliferative Neoplasms Whilst Promoting a TH17 Phenotype
Shahram Kordasti,Thomas Seidl,Pilar Perez Abellan,N S B Thomas,Ghulam J. Mufti,Claire N. Harrison,Donal P. McLornan +6 more
TL;DR: Tregs were reduced in number and there was a considerable increase in the percentage of “cytokine negative” or “silent” T effector cells by FACS analysis compared to untreated or vehicle treated cells, suggesting the immune signature remains largely undescribed in MPN as does the effect of JAK inhibition on the immune subsets in this disease.
Journal ArticleDOI
Clinical Significance of MPL Mutations in Essential Thrombocythemia: Analysis of the PT-1 Cohort.
Philip A. Beer,Peter J. Campbell,Wendy N. Erber,Linda M. Scott,Anthony J. Bench,David Bareford,Wilkins Bridget,Keith Wheatley,Georgina Buck,Claire N. Harrison,Anthony R. Green +10 more
TL;DR: The results describe the prevalence, clinical features and laboratory manifestations of MPL mutations in the context of a large prospective study of ET.
Journal ArticleDOI
Management of MPN beyond JAK2
TL;DR: This chapter considers whether there is evidence that thrombocytosis contributes to the complications known to be associated with MPN, and reviews current ideas for risk stratification and management of essential thromBocythemia and polycythemia vera.